mRNA and nucleic acid CDMO with GMP manufacturing and bioprocess testing
Maravai LifeSciences manufactures nucleic acids, mRNA precursors, and enzyme products for vaccine and gene-therapy developers, alongside bioprocess impurity detection assays. The hiring acceleration skews toward manufacturing and operations roles—particularly GMP services execution—while projects center on technology transfer from R&D to regulated manufacturing and Japan market entry, signaling scaling of commercial-stage production capacity.
Maravai LifeSciences is a public San Diego biotech company serving life sciences developers through three core business lines: nucleic acid and mRNA production (under brands like TriLink), enzyme development for PCR and molecular diagnostics, and bioprocess quality testing (impurity detection, product safety assays). The company holds over 1,500 products and proprietary technologies—including CleanCap mRNA capping and MockV viral safety assays—and operates across multiple GMP manufacturing sites. Customers include vaccine manufacturers, gene-therapy developers, and CDMOs navigating clinical and commercial scale.
Enterprise systems: Salesforce, NetSuite, Microsoft 365, Azure, AWS. Security and infrastructure: Intune, Active Directory, Azure AD, VMware, Veeam, Windows Server, IAM. No major platform adoptions or replacements noted.
San Diego, California. Public company with 501–1,000 employees, founded in 2014. Actively expanding manufacturing capacity and opening sales operations in Japan.
Other companies in the same industry, closest in size